NEW YORK, Aug. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning,
Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Argos Therapeutics,
Inc. (OTC:ARGS), Triumph Group, Inc. (NYSE:TGI), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Egalet Corporation (NASDAQ:EGLT), Hertz
Global Holdings, Inc (NYSE:HTZ), and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), including updated fundamental summaries,
consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
ARGS DOWNLOAD: http://Fundamental-Markets.com/register/?so=ARGS
TGI DOWNLOAD: http://Fundamental-Markets.com/register/?so=TGI
RIGL DOWNLOAD: http://Fundamental-Markets.com/register/?so=RIGL
EGLT DOWNLOAD: http://Fundamental-Markets.com/register/?so=EGLT
HTZ DOWNLOAD: http://Fundamental-Markets.com/register/?so=HTZ
ACAD DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACAD
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Argos
Therapeutics, Inc. (OTC:ARGS), Triumph Group, Inc. (NYSE:TGI), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Egalet Corporation
(NASDAQ:EGLT), Hertz Global Holdings, Inc (NYSE:HTZ), and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on a fundamental level and
outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management
discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's
readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone
summaries and as such, important information may be missing from these samples. Please download the entire research report, free of
charge, to ensure you are reading all relevant material information. All information in this release was accessed August 29th,
2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
ARGOS THERAPEUTICS, INC. (ARGS) REPORT OVERVIEW
Argos Therapeutics' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Argos Therapeutics reported revenue of $0.05MM vs
$0.07MM (down 22.24%) and basic earnings per share -$0.61 vs -$4.13. For the twelve months ended December 31st, 2017 vs December
31st, 2016, Argos Therapeutics reported revenue of $1.90MM vs $0.95MM (up 100.89%) and basic earnings per share -$13.45 vs -$33.14.
Argos Therapeutics is expected to report earnings on November 8th, 2018. The report will be for the fiscal period ending September
30th, 2018.
To read the full Argos Therapeutics, Inc. (ARGS) report, download it here: http://Fundamental-Markets.com/register/?so=ARGS
-----------------------------------------
TRIUMPH GROUP, INC. (TGI) REPORT OVERVIEW
Triumph Group's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Triumph Group reported revenue of $832.90MM vs
$781.69MM (up 6.55%) and basic earnings per share -$1.54 vs -$0.04. For the twelve months ended March 31st, 2018 vs March 31st,
2017, Triumph Group reported revenue of $3,198.95MM vs $3,532.80MM (down 9.45%) and basic earnings per share -$8.60 vs -$0.87.
Triumph Group is expected to report earnings on November 14th, 2018. The report will be for the fiscal period ending September
30th, 2018. The reported EPS for the same quarter last year was $0.52. The estimated EPS forecast for the next fiscal year is $2.18
and is expected to report on May 9th, 2019.
To read the full Triumph Group, Inc. (TGI) report, download it here: http://Fundamental-Markets.com/register/?so=TGI
-----------------------------------------
RIGEL PHARMACEUTICALS, INC. (RIGL) REPORT OVERVIEW
Rigel Pharmaceuticals' Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, Rigel Pharmaceuticals reported revenue
of $4.48MM vs $20.38MM (down 78.00%) and basic earnings per share -$0.62 vs -$0.73. Rigel Pharmaceuticals is expected to report
earnings on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same
quarter last year was -$0.14. The estimated EPS forecast for the next fiscal year is -$0.53 and is expected to report on March 5th,
2019.
To read the full Rigel Pharmaceuticals, Inc. (RIGL) report, download it here: http://Fundamental-Markets.com/register/?so=RIGL
-----------------------------------------
EGALET CORPORATION (EGLT) REPORT OVERVIEW
Egalet's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Egalet reported revenue of $7.44MM vs $6.26MM (up
18.99%) and basic earnings per share -$0.22 vs -$1.04. For the twelve months ended December 31st, 2017 vs December 31st, 2016,
Egalet reported revenue of $26.14MM vs $16.96MM (up 54.07%) and basic earnings per share -$2.05 vs -$3.70. Egalet is expected to
report earnings on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for
the same quarter last year was -$0.46. The estimated EPS forecast for the next fiscal year is -$0.60 and is expected to report on
March 11th, 2019.
To read the full Egalet Corporation (EGLT) report, download it here: http://Fundamental-Markets.com/register/?so=EGLT
-----------------------------------------
HERTZ GLOBAL HOLDINGS, INC (HTZ) REPORT OVERVIEW
Hertz Global's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Hertz Global reported revenue of $2,389.00MM vs
$2,224.00MM (up 7.42%) and basic earnings per share -$0.75 vs -$1.90. For the twelve months ended December 31st, 2017 vs December
31st, 2016, Hertz Global reported revenue of $8,803.00MM vs $8,803.00MM (unchanged) and basic earnings per share $3.94 vs -$5.85.
Hertz Global is expected to report earnings on November 8th, 2018. The report will be for the fiscal period ending September 30th,
2018. The reported EPS for the same quarter last year was $1.42. The estimated EPS forecast for the next fiscal year is $0.40 and
is expected to report on February 26th, 2019.
To read the full Hertz Global Holdings, Inc (HTZ) report, download it here: http://Fundamental-Markets.com/register/?so=HTZ
-----------------------------------------
ACADIA PHARMACEUTICALS INC. (ACAD) REPORT OVERVIEW
ACADIA Pharmaceuticals' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, ACADIA Pharmaceuticals reported revenue of
$57.06MM vs $30.48MM (up 87.25%) and basic earnings per share -$0.51 vs -$0.55. For the twelve months ended December 31st, 2017 vs
December 31st, 2016, ACADIA Pharmaceuticals reported revenue of $124.90MM vs $17.33MM (up 620.68%) and basic earnings per share
-$2.36 vs -$2.34. ACADIA Pharmaceuticals is expected to report earnings on November 6th, 2018. The report will be for the fiscal
period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.53. The estimated EPS forecast for the
next fiscal year is -$1.55 and is expected to report on February 26th, 2019.
To read the full ACADIA Pharmaceuticals Inc. (ACAD) report, download it here: http://Fundamental-Markets.com/register/?so=ACAD
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading
brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals
worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA®
BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst®
(CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes
qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers.
Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit
firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries
regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail
at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental
Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result
from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the
material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the
publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm,
investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full
disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network
manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority,
Inc.
